Business
ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG’ at ASCO GU
A positive difference in physical function in responders versus non-responders was noted The study indicates a favorable risk/benefit ratio and quality of
About this update from Immunitybio, Inc.
[{"type":"text","content":"\n\nA positive difference in physical function in responders versus non-responders was noted\n\n\nThe study indicates a favorable risk/benefit ratio and quality of life following N-803 plus BCG is comparable to BCG alone\n\n\n CULVER CITY, Calif.--(BUSINESS WIRE)--\nImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced Dr. Karim Chamie, Associate Professor of Urology at UCLA, will be presenting “Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG” at the ASCO Genitourinary Cancers Symposium (ASCO GU) conference in San Francisco, February 16-18. The Food and Drug Administration (FDA) is currently reviewing the Biologics License Application (BLA) for ImmunityBio’s N-803 plus BCG for the treatment of NMIBC CIS with a Prescription Drug User Fee Act (PDUFA) date of May 23, 2023.\n\nDetails about the presentation are below:\n\nDate: February 16, 2023\nTrack: Urothelial Carcinoma, Prostate Cancer-Advanced\nSub-Track: Symptoms, Toxicities, Patient-Reported Outcomes and Whole-Person Care\nTitle: Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG\nPresenter: Dr. Karim Chamie, Associate Professor of Urology at UCLA\nSession: Poster Session B: Prostate Cancer and Urothelial Carcinoma\nAbstract #: 495\nLocation: Poster Board J17\nSession Times: 11:30 a.m.-1:00 p.m.; 5:45-6:45 p.m. PST\n\nParticipants are also invited to attend ImmunityBio’s Medical Affairs booth (#65). For full session details and scientific presentation listings, please see the ASCO GU online program.\n\nAbout ImmunityBio\n\nImmunityBio is a vertically-integrated, clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company’s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.\n\nN-803...